2/16/2022

speaker
Operator

Good afternoon, ladies and gentlemen, and welcome to Marker Therapeutics conference call. At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded. It's now my pleasure to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Mr. Kim, please go ahead.

speaker
Tony Kim
Chief Financial Officer

Thanks, Operator. Welcome, everyone, and thank you for joining us this afternoon for our clinical program and technical operations update call. With me today are Peter Huang, our President and Chief Executive Officer, Dr. Juan Vera, our Chief Scientific and Chief Operating Officer, and Dr. Maithili Connero, our Chief Medical Officer. This afternoon, we issued a news release that you can find on our website at markettherapeutics.com, which includes a summary of initial results from the safety lead-in portion of our Phase II AML trial, as well as updates on our new manufacturing process and an overview of our near-term clinical plans. Before we begin, as a reminder, we will be making forward-looking statements regarding our financial outlook in addition to regulatory, product development, and commercialization plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent 10-K on file with the SEC. I would now like to turn the call over to Peter.

speaker
Peter Huang
President and Chief Executive Officer

Good afternoon, everyone, and thank you for joining us today. Marker's off to a strong start in 2022, and we've made considerable progress in advancing our Phase 2 AML trial. In just a moment, I'll be making a few remarks about our company's progress and providing an overview of our plans for the remainder of 2022. I'll then hand off the call to Maithili Kaneru, who will walk through the initial results from the safety lead-in portion of our ongoing Phase 2 AML trial. After that, Juan will provide an overview of the T-cell manufacturing improvements that we're currently implementing. and I will wrap up the call with several important pipeline updates and a summary of key milestones. Then we will open up the call to questions. Moving to the first slide, as you know, our clinical team has been hard at work advancing our phase two AML trial, investigating MT401, our lead multi-TAA specific T cell product candidate. Today, we're excited to announce encouraging initial results from the safety leading cohort. MT401 demonstrated a strong safety profile with no SAEs or neurotoxicity observed. While we're presently working with small patient numbers, we were extremely pleased with the outcome. Of note, MT401 generated an objective clinical response in a patient with measurable residual disease. MRD is a form of active disease in AML that is generally considered to be a precursor to frank relapse. This patient converted to MRD negative status after receiving treatment, meaning that that patient's disease was no longer detectable and the patient was no longer at high risk of frank relapse. We're also excited to share details on our improved new T-cell manufacturing process, which will be implemented with MT401 in the Phase II AML trial and other products in development. Beyond the significant process improvements we announced and implemented at the beginning of last year, Marker has continued to refine and improve its multi-TAA-specific T-cell manufacturing processes. we're pleased to announce that our development team has been able to achieve a number of additional process improvements, which we have already reviewed with the FDA. Our new manufacturing process is designed to deliver a more potent product, bolster tumor killing, and be manufactured in only nine days. This is of particular significance to MRD-positive AML patients who have a high likelihood of frank relapse and negative outcomes. With this reduced manufacturing time, we can potentially treat more MRD-positive patients during their short therapeutic window. Today, we're also announcing the expansion of our pipeline and additional company-sponsored clinical programs, beginning with pancreatic cancer, our first trial evaluating a multi-TAA cell therapy for the treatment of solid tumors, as well as a new trial in lymphoma. We plan to file INDs for our second multi-TAA-specific T cell therapy candidate, MT601, by year end and initiate clinical trials in these indications in 2023. We're also excited to expand our AML trial with MT401-OTS, a scalable off-the-shelf therapy with the potential to match patients to treatment in under three days. Looking ahead, we plan to develop additional off-the-shelf products in lymphoma and ovarian cancer with the goal of significantly improving patient access to promising cell therapies. With that, I'd like to turn the call over to Dr. Maithili Kaneru, who will provide further details on our Phase II AML trial.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-